Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions

Ther Deliv. 2022 Mar;13(3):167-186. doi: 10.4155/tde-2021-0060. Epub 2022 Jan 14.


IGF-1Rs enact a significant part in cancer growth and its progress. IGF-1R inhibitors were encouraged in the early trials, but the patients did not benefit due to the unavailability of predictive biomarkers and IGF-1R system complexity. However, the linkage between IGF-1R and cancer was reported three decades ago. This review will shed light on the IGF-1R system, targeting IGF-1R through monoclonal antibodies, reasons behind IGF-1R trial failure and future directions. This study presented that targeting IGF-1R through monoclonal antibodies is still effective in cancer treatment, and there is a need to look for future directions. Cancer patients may benefit from using mAbs that target existing and new cancer targets, evidenced by promising results. It is also essential that the academician, trial experts and pharmaceutical companies play their role in finding a treatment for this deadly disease.

Keywords: IGF-1R; colorectal cancer; monoclonal antibodies (mAbs); prostate cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Humans
  • Male
  • Prostate*
  • Receptor, IGF Type 1


  • Antibodies, Monoclonal
  • Receptor, IGF Type 1